Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2025 May 28;20(5):e0316983. doi: 10.1371/journal.pone.0316983

The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability

Alma Lorena Perez 1, Magdalena Zamora 1, Manuel Bahena 1, Regina Aramburo-Williams 1, Elva Adan-Castro 1, Daniela Granados-Carrasco 1, Thomas Bertsch 2, Jakob Triebel 2, Gonzalo Martinez de la Escalera 1, Juan Pablo Robles 1,3,‡, Carmen Clapp 1,‡,*
Editor: Mohamed Abdelkarim4
PMCID: PMC12118997  PMID: 40435350

Abstract

Introduction

Cancer cells drive the increase in vascular permeability mediating tumor cell extravasation and metastatic seeding. VIAN-c4551, an antiangiogenic peptide analog of vasoinhibin, inhibits the growth and vascularization of melanoma tumors in mice. Because VIAN-c4551 is a potent inhibitor of vascular permeability, we evaluated whether its antitumor action extended to a reduction in metastasis generation.

Methods

Circulating levels of vascular endothelial growth factor (VEGF), lung vascular permeability, melanoma cell extravasation, and melanoma pulmonary nodules were assessed in C57BL/6J mice intravenously inoculated with murine melanoma B16-F10 cells after acute treatment with VIAN-c4551. VEGF levels, transendothelial electrical resistance, and transendothelial migration in cocultures of B16-F10 cells and endothelial cell monolayers supported the findings.

Results

B16-F10 cells increased circulating VEGF levels and elevated lung vascular permeability 2 hours after inoculation. VIAN-c4551 prevented enhanced vascular permeability and reduced melanoma cell extravasation after 2 hours and the number and size of macroscopic and microscopic melanoma tumors in lungs after 17 days. In vitro, VIAN-c4551 suppressed the B16-F10 cell-induced and VEGF mediated increase in endothelial cell monolayer permeability and the transendothelial migration of B16-F10 cells. No detrimental effect of VIAN-c4551 was observed on hematological, biochemical, and histological parameters after its intravenous administration in mice for 14 days.

Conclusions

These findings support the inhibition of distant vascular permeability for the prevention of tumor metastasis and unveil the anti-vascular permeability factor VIAN-c4551 as a potential and safe therapeutic drug able to prevent metastasis generation by lowering the extravasation of melanoma cells.

Introduction

Metastasis is the major cause of cancer death, yet metastatic activity is not the main end point of current anti-cancer treatments, and the process remains elusive [1]. A critical step in early metastasis is the exiting of tumor cells from the circulation at distant sites. Extravasation depends on the ability of tumor cells to transmigrate through the vessel wall. Tumor cells can disrupt the vascular barrier at metastatic sites by secreting vascular permeability factors [2], including VEGF, the most powerful vascular permeability stimulator [3]. The development of drugs targeting the extravasation of tumor cells offers a hopeful approach to prevent or delay the metastatic outgrowth of cancer.

VIAN-c4551 is a promising anti-cancer drug. It is a highly potent antiangiogenic cyclic heptapeptide analog of vasoinhibin [4], an endogenous antiangiogenic and vascular permeability inhibitor with significant therapeutic potential [5]. Vasoinhibin inhibits endothelial cell proliferation, migration, survival, and permeability in response to VEGF and other angiogenic and vascular permeability stimulators (basic fibroblast growth factor, bradykinin, interleukin 1β) [4,5]. Vasoinhibin helps restrict physiological angiogenesis in the retina and cartilage [6,7] and inhibits pathological angiogenesis and vasopermeability in experimental models of vasoproliferative retinopathies [8], inflammatory arthritis [9], peripartum cardiomyopathy [10], preeclampsia [11] and cancer [12]. Vasoinhibin gene transfer in prostate [13], colon [14], mammary gland [15] and melanoma [16,17] cancer cells reduce primary tumor growth and neovascularization. Furthermore, vasoinhibin gene therapy delivered two days after the intravenous inoculation of melanoma cells reduces the number and size of lung melanoma nodules [16] indicating its ability to inhibit the growth of metastasis after the engraftment of tumor cells in the metastatic region but there is no information of an action before metastatic spreading.

However, the direct use of vasoinhibin as an anti-cancer therapeutic agent is hampered by difficulties in its recombinant production [18]. These difficulties have been overcome by the development of VIAN-c4551, a vasoinhibin analog with improved pharmacological properties that conserves the efficacy and potency of vasoinhibin [4]. VIAN-c4551 inhibits VEGF-induced proliferation and permeability of endothelial cells with a potency like vasoinhibin (IC50 = 150 pM) and is orally active to inhibit melanoma tumor growth and vascularization in mice [4,19]. Because extravasation is a pivotal step of metastasis involving tumor vasopermeability factors such as VEGF [2,3] and VIAN-c4551 is a potent inhibitor of VEGF-induced vasopermeability [4,19], we aimed to investigate whether the anti-tumor action of VIAN-c4551 extended to the inhibition of the VEGF-mediated vascular permeability causing the extravasation and metastatic spread of melanoma cells.

Methods

Reagents

VIAN-c4551 (>95% pure) was synthesized by GenScript (Piscataway, NJ, USA).

Cell culture

The mouse melanoma B16-F10 cell line (CRL-6475, ATCC, Manassas, VA, USA) expressing (B16-F10-GFP) or not the green fluorescent protein, the NIH/3T3 mouse embryonic fibroblast cell line (CRL-1658, ATCC), the human breast cancer cell lines MCF7 (HTB-22, ATCC) and MDA-MB-231 (HTB-26, ATCC), and the bovine umbilical vein endothelial cell line (BUVEC-E6E7), generated and characterized as reported [20], were cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM) (12100–038, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (26140–079, GIBCO) and 100 U/ml penicillin-streptomycin (L0022, Biowest, Bradenton, FL, USA). Human umbilical vein endothelial cells (HUVEC) were obtained [21] and cultured in F12K medium (21127–022, GIBCO) supplemented with 20% FBS, 100 µg/ml heparin (H3149, Sigma-Aldrich, Saint Louis, MO, USA), 25 µg/ml ECGS (356006, Corning Inc., Corning, NY, USA), and antibiotics.

Vascular permeability in vitro

BUVEC-E6E7 were seeded on 6.5 mm transwell clear polyester membrane inserts (Corning) with pore sizes of 0.4 μm at an initial density of 7.2 x 103 cells per well (30% confluency). After approximately 96 hours, transendothelial electrical resistance (TEER) measured by the EVOM2 Epithelial Voltohmmeter (World Precision Instruments, Sarasota, FL) stabilized around 55 Ω.cm2 (reflecting a confluent monolayer) and treatments started. They included vehicle (DMEM 10% FBS), 100 nM VIAN-c4551, or 2 µg anti-VEGF (Ranibizumab, Lucentis®, Novartis, Basel, Switzerland) for 1 hour before adding B16-F10 cells (3.5 x 104 cells in 100 µl per well) or applying 100 µl/well of medium conditioned by B16-F10 cells (B16-F10-CM) or medium conditioned by 3T3 cells (3T3-CM) to the luminal side. TEER was measured over a 6-hour period, with high TEER values indicating a tight, impermeable barrier, and lower values indicating increased permeability. In other experiments, HUVEC were seeded at an initial density of 5 x 103 cells/well (40% confluency) on 6.5 mm transwell with 0.4 µm pores. The TEER stabilized around 55 Ω.cm2 after approximately 96 hours, and the monolayers were then treated with vehicle or 100 nM VIAN-c4551 for 1 hour followed by the addition of 100 µl/well of B16-F10-CM, or medium conditioned either by MCF-7 cells (MCF-7-CM) or MDA-MB-231 cells (MDA-MB-231-CM). TEER was measured over a 2-hour period. All CM were from cells grown to 80% confluency for 48 h. VEGF levels in the CM of B16-F10 cells treated or not with 100 nM VIAN-c4551 were measured by the enzyme-linked immunosorbent assay (ELISA, Quantikine mouse VEGF kit #MMV00, R&D System, Minneapolis, MN, USA).

Actin distribution

A previously described method was used [22]. BUVEC-E6E7 were seeded on coverslips placed in 24-well plates and grown to confluence. When the monolayer was completely formed, cells were treated for 1 hour with 100 nM VIAN-c4551, 2 µg anti-VEGF (Ranibizumab, Lucentis®, Novartis) or PBS followed by the addition of 100 µl B16-F10-CM or vehicle (PBS) for 1 hour. Cells were then washed, fixed with 4% paraformaldehyde for 20 minutes, permeabilized with 0.1% Triton X-100 for 15 minutes, stained for actin with 160 nM rhodamine–phalloidin (R415, Thermo Fisher Scientific) for 1 hour in darkness, and counterstained with 5 μg/ml Hoechst 33342 (B2261, Sigma-Aldrich). Finally, the coverslips were washed, mounted, and observed under a fluorescent microscope (Olympus BX60, Tokyo, Japan).

Transendothelial migration assay

BUVEC-E6E7 (7.2 x 103) were seeded on 6.5 mm transwell membrane inserts with 8 μm pores coated with 0.38 mg/ml matrigel (354234, Corning). Upon confluency (55 Ω.cm2, revealed by the EVOM2 resistance tester) monolayers were treated for 1 hour with 100 nM VIAN-c4551 into the upper (luminal) chamber followed by the addition of fluorescent B16-F10-GFP cells (3.5 x 104 cells per well). Conditioned medium of B16-F10 cells containing 10% FBS was added into lower (abluminal) chamber to serve as chemoattractant. After incubation for 16 hours, cells in the luminal side were washed and migrating cells in the abluminal side were fixed, observed by an inverted fluorescent microscope (Olympus IX51), and quantified using the Image Pro Plus software (Version 7, Media Cybernetics Inc., Rockville, MD, USA).

Animals

Adult female C57BL/6J mice (8–12 weeks) were selected based on their use in preceding studies showing the inhibition of melanoma tumor growth and neovascularization by vasoinhibin [16] and VIAN-c4551 [4]. Mice were housed under standard laboratory conditions (22°C; 12h/12h light/dark cycle; free access to food and water). Experiments were approved by the Bioethics Committee of the Institute of Neurobiology of the National University of Mexico (UNAM) according to the US National Research Council’s Guide for the Care and Use of Laboratory Animals (Eighth Edition, National Academy Press, Washington, D.C., USA). B16-F10 cells were trypsinized, washed and resuspended in PBS. Restrained, non-anesthetized mice were injected into the lateral tail vein with vehicle (saline) or 1 mg/kg body weight (b.w.) VIAN-c4551, the effective dose characterized in a preceding study [4]. Thirty minutes later, 2 x 105 B16-F10 or B16-F10-GFP cells resuspended in 100 µl PBS or 100 µl PBS were injected into the tail vein. Mice in control and treatment groups were selected at random and identified with ear tags to minimize potential confounders. Groups were divided to either collect blood, evaluate pulmonary vascular permeability, or quantify melanoma cell extravasation 2, 4 or 8 hours after B16-F10 cell intravenous (i.v.) inoculation. Other groups were euthanized 17 days after B16-F10 cell injection when their lungs were harvested to evaluate macroscopic and microscopic melanoma tumors. Animals were monitored every other day and showed no apparent signs of discomfort, loss of body weight, or impaired quality of life that merited early euthanasia. At endpoint times (2–8 hours or 17 days post B16-F10 cell inoculation), mice were anesthetized (60% ketamine/40% xylazine; 1µl/g b.w.) before perfusion and euthanized by CO2 inhalation or an overdose of ketamine/xylazine and decapitation. A total of 132 animals were used, no animals died or had to be excluded. Investigators trained in animal care and handling performed all experiments and were blind to treatment assignments when evaluating outcomes. Sample size was defined based on reliable differences.

Pulmonary vascular permeability

Vascular permeability was assessed by the extravasation of albumin stained by the Evans blue dye as previously described [23] with some modifications. Briefly, the Evans blue dye (50 µl, 45 mg/kg; E2129, Sigma-Aldrich) was i.v. injected after B16-F10 cell inoculation 1 hour before perfusion. Five hundred µl of blood was withdrawn from the heart to measure Evans blue concentration in plasma, and mice were then perfused for 2 minutes via the right ventricle with 70 ml PBS (pH 3.5 at 37°C). Lungs were dried at 72°C for 24 hours and the Evans blue dye extracted by incubating each lung in 300 μl formamide (F7503, Sigma-Aldrich) for 18 hours at 72°C. Absorbance was measured in the supernatant at 620 nm using the Varioskan Flash spectrophotometer (Thermo Fisher Scientific). The dye concentration in the extracts was calculated using a standard curve of Evans blue in formamide and normalized to the lung and body weight and to the Evans blue concentration in plasma. VEGF levels in serum were measured by ELISA (Quantikine mouse VEGF kit #MMV00, R&D System).

Lung metastasis melanoma model

Lungs were harvested and placed in Fekete’s solution as reported [24]. Tumor nodules were evaluated macroscopically on the lung surface with a stereoscope (Leica Zoom 2000, Leica Biosystems, Nussloch, Germany) and their number and size quantified using the ImageProPlus analysis software by 2 independent operators blind to treatment. Samples were fixed in 10% formalin for 48 hours, dehydrated in ethanol, and embedded in paraffin. Seven-µm-thick paraffin sections from lungs were deparaffinized with xylol, rehydrated in graded alcohol series, stained with Harris’s hematoxylin and eosin solution, and digitalized using Aperio Image ScanScope (Leica) and the number and area of microscopic nodules were quantified with the ImageProPlus analysis software.

Lung melanoma cell extravasation

Mice were perfused with 10 ml PBS for 10 minutes (1ml/minute) via the right ventricle with PBS (pH 7.4 at 37°C) to remove nonadhered melanoma cells. The left and right lungs were processed for RT-qPCR and histological evaluation, respectively. RNA was isolated using TRIzol (15596018, Invitrogen, Thermo Fisher Scientific) and retrotranscribed with the high-capacity cDNA reverse transcription kit (4368813 Applied Biosystems, Thermo Fisher Scientific). Polymerase chain reaction (PCR) products were obtained and quantified using Maxima SYBR Green qPCR Master Mix (K0223, Thermo Fisher Scientific) in a final reaction containing 20 ng of cDNA and 0.5 μM of each of the following primer pairs for murine genes: GFP fwd (5’-AAGTCGTGCTGCTTCATGTG-3’), GFP rev (5’-CAAGCTGACCCTGAAGTTCA-3’), GAPDH fwd (5’- GAAGGTCGGTGTGAACGGATT-3’) and GAPDH rev (5’- TGACTGTGCCGTTGAATTTG-3’). Amplification consisted of 40 cycles of 10 seconds at 95 °C, 30 seconds at the annealing temperature of each primer pair, and 30 seconds at 72 °C. The mRNA expression levels were calculated by the 2−ΔΔCT method. The right lung was fixed in 4% paraformaldehyde for 24 hours, cryoprotected with 4% sucrose (4072-05, JT Baker, Phillipsburg, NJ, USA) for 48 hours, frozen and cryosectioned (20 µm) (Leica CM1850). Sections were observed under a fluorescent microscope (Olympus BX60) to visualize extravasated B16-F10-GFP cells.

Toxicity evaluation

A sub-acute toxicity analysis was performed in mice treated with VIAN-c4551. Briefly, six female mice (6-week-old) per group were daily injected i.v. into the lateral tail vein with vehicle (saline) or with a single dose of VIAN-c4551 (1 or 10 mg/kg) for 14 days. On the following day, mice were fasted for 4 hours, weighed, euthanized by CO2 inhalation, and the blood, withdrawn by cardiac puncture was placed in heparin microtubes for the evaluation of hematological and biochemical parameters. Heart, lungs, liver, spleen, and both kidneys were dissected, weighed and collected for histopathological examination. Tissues were fixed in buffered formalin (10% formaldehyde) and processed by independent certified veterinary pathologists (Biocel Laboratorio Veterinario Queretaro, Mexico).

Statistical analysis

The overall significance threshold was set at P < 0.05. The unpaired two-tailed t-test was used for two-group comparisons and one-way or two-way ANOVA for more than two groups. After ANOVA, Tukey, Dunnett and Sidak post hoc tests were performed using GraphPad Prism version 10.4.0 for macOS (GraphPad Software, San Diego, CA, USA).

Results

VIAN-c4551 reduces the permeability of pulmonary vessels stimulated by B16-F10 cells

Tumor cells stimulate the vascular permeability needed for their extravasation at metastatic sites [2,25]. To evaluate melanoma cell-induced vascular leakage, mice were injected i.v. with B16-F10 cells and vascular permeability determined in lungs by the extravasation of Evans blue stained albumin at different times post-B16-F10 cell inoculation (Fig 1a). Lung vessels responded to circulating B16-F10 cells by the accumulation of the Evans blue tracer (Fig 1b) with the increase in vascular permeability being highest and lowest at 2 hours and 8 hours post-treatment, respectively (Fig 1b and c). The timing of lowest leakage (8 hours) coincided with the reported time at which most melanoma cells have extravasated following their systemic inoculation [26] and suggested 2 hours post-tumor cell injection as the window of opportunity for modifying the exit of tumor cells from the intravascular to the extravascular compartment.

Fig 1. B16-F10 cells stimulate lung vascular permeability.

Fig 1

Open in a new tab

(a) Timeline of the evaluation of pulmonary vascular permeability after intravenous inoculation of B16-F10 cells. (b) Photographs of representative lungs showing the accumulation of Evans blue-stained albumin at different times post-B16-F10 cell delivery. (c) Quantification of Evans blue-stained albumin as index of lung vascular permeability. Data from 2 independent experiments (n = 4) is graphed using a box and a whisker plot; the box frames the interquartile range, the horizontal line indicates the median, and the whiskers the min and max values. The mean is indicated by +. *P = 0.02, **P = 0.01, ***P < 0.001 (One-way ANOVA, Tukey’s multiple comparison test).

VIAN-c4551 or vehicle (saline) was i.v. injected 30 minutes before the systemic inoculation of B16-F10 cells or the i.v. injection of PBS followed by the evaluation of lung vascular leakage or serum VEGF levels after 2 hours (Fig 2a). As expected, the B16-F10 cell-induced accumulation of the Evans blue tracer was anatomically evident in lungs (Fig 2b) and accounted for a 2.5-fold increase in vascular permeability relative to PBS treated mice (Fig 2c). VIAN-c4551 prevented the upregulation of lung vascular permeability in response to melanoma cells without affecting basal vasopermeability in the absence of cells (Fig 2b and c). Because VEGF is a major vascular permeability stimulator produced by tumor cells, including B16-F10 cells [2,3], and VIAN-c4551 inhibits VEGF-induced vasopermeability [19], the circulating levels of VEGF were determined 2 hours post-tumor cell inoculation or PBS injection (Fig 2a). B16-F10 cells increased serum VEGF levels, and VEGF values were not altered by VIAN-c4551 (Fig 2d). We conclude that VIAN-c4551 abrogates lung vascular permeability not by blocking the melanoma cell release of VEGF but by inhibiting the vasopermeability action of the VEGF released by melanoma cells.

Fig 2. VIAN-c4551 prevents the increase of vascular permeability stimulated by melanoma cells.

Fig 2

Open in a new tab

(a) Timeline of the experiment: VIAN-c4551 or vehicle (Veh) were i.v. injected 30 minutes before the i.v. delivery of B16-F10 cells or PBS. Pulmonary vascular permeability or VEGF levels were evaluated 2 hours post-tumor cells or PBS. (b) Photographs of representative lungs showing the accumulation of Evans blue-stained albumin as index of pulmonary vascular permeability. (c) Quantification of lung vascular permeability in Veh- and VIAN-c4551-treated mice after i.v. injection of PBS or B16-F10 cell inoculation. Data from 3 independent experiments (n = 9) are graphed in a box and a whisker plot; the box frames the interquartile range, the horizontal line indicates the median, and the whiskers the min and max values. The mean is indicated by +. ***P < 0.001 (Two-way ANOVA, Sidak’s multiple comparison test). (d) VEGF levels in serum from Veh- and VIAN-c4551-treated mice after injection of PBS or B16-F10 cell inoculation. Values are box and whiskers plot from 2 independent experiments (n = 6), ***P < 0.001 (Two-way ANOVA, Sidak’s multiple comparison test).

Because a single i.v. injection of VIAN-c4551 prevented melanoma cell-induced pulmonary leakage at 2 hours, when melanoma cells are circulating [26], we hypothesized that VIAN-c4551 decreases the vascular exit of tumor cells and, thereby, reduces lung melanoma metastasis.

A single administration of VIAN-c4551 reduces melanoma metastatic nodules in lungs

To test whether the inhibition of lung vascular leakage by VIAN-c4551 interferes with pulmonary metastasis, VIAN-c4551 or vehicle (saline) was injected i.v. 30 minutes before the systemic inoculation of B16-F10 cells and lungs were collected after 17 days to evaluate metastatic nodules (Fig 3a). Representative images showing the ventral and dorsal views of left and right pulmonary lobes showed many superficial macroscopic black nodules in vehicle-treated mice and only a few in mice treated with VIAN-c4551 (Fig 3b). In agreement, VIAN-c4551 reduced by 55% the number and by 50% the size of macroscopic nodules at the lung surface (Fig 3c and d). Moreover, the histological evaluation of five longitudinal lung sections showed that VIAN-c4551 reduced by 56% and by 57% the number and size of microscopic melanoma nodules, respectively (Fig 3e-g). These findings implied that the inhibition of melanoma cell-induced vascular leakage by VIAN-c4551 is sufficient to strongly inhibit B16-F10 cell metastasis in lungs and prompted addressing this mechanism further.

Fig 3. A single administration of VIAN-c4551 reduces the number and size of lung melanoma metastases in mice.

Fig 3

Open in a new tab

(a) Timeline of the experiment: VIAN-c4551 or vehicle (Veh) were injected i.v. 30 minutes before the i.v. inoculation of B16-F10 cells. Lung melanoma nodules were evaluated 17 days post-tumor cell delivery. (b) Representative ventral and dorsal views of the left lung and the four right lobes of a mice treated with Veh or VIAN-c4551. Quantification of the number (c) and size (d) of macroscopic melanoma nodules on the lung surface. (e) Representative lung sections stained with hematoxylin/eosin showing microscopic melanoma nodules (arrows) (scale = 200 μm). Quantification of the number (f) and size (g) of internal microscopic melanoma nodules in lungs. Numbers of nodules are graphed in a box and a whisker plot; the box represents the interquartile range, the horizontal line indicates the median, and the whiskers the min and max values. Size is graphed in a violin plot showing median and quartiles. The mean is indicated by +. Data from 3 independent experiments (n = 13). **P = 0.008, ***P < 0.001 vs Veh (unpaired t-test).

VIAN-c4551 inhibits the melanoma cell-induced permeability of endothelial cell monolayers mediated by VEGF

Transendothelial electrical resistance (TEER) of cellular monolayers measures the integrity of cell junctions and it is a quantitative indicator of the monolayer permeability [27]. B16-F10 cells (Fig 4a) and their conditioned media (B16-F10-CM) (Fig 4b) decreased the TEER of bovine umbilical vein endothelial cell (BUVEC-E6E7) monolayers throughout a 6-hour incubation period. VIAN-c4551 prevented the reduction of TEER induced by both B16-F10 and B16-F10-CM while VIAN-c4551 alone had no effect. Likewise, the anti-VEGF monoclonal fragment ranibizumab blocked the TEER reduction in response to B16-F10 and B16-F10-CM, indicating that VEGF is a substantial contributor to melanoma cell-induced hyperpermeability (Fig 4a and b). In agreement, VEGF accumulated overtime in the B16-F10-CM (Fig 4c) and, as expected from in vivo data (Fig 2d), its levels were not affected by VIAN-c4551. Increased vascular permeability due to weakened endothelial cell junctions associates with the redistribution of the actin cytoskeleton that leads to cell contraction [28,29]. The actin cytoskeleton was therefore evaluated by phalloidin-TRITC staining of BUVEC-E6E7 monolayers exposed 1 hour to the B16-F10-CM. The B16-F10-CM altered the actin cytoskeleton as revealed by increased fluorescence and frequent contracted cell bodies and these changes were prevented by VIAN-c4551 and anti-VEGF (Fig 4d). To evaluate the functional link between vasopermeability and metastatic activity, we turned to 3T3 cells, a mouse cell line derived from embryonic fibroblasts that is devoid of metastatic activity [30]. Their conditioned media (3T3-CM) did not modify the TEER of BUVEC-E6E7 monolayers throughout a 6-hour incubation period (Fig 4e). BUVEC-E6E7 is a well characterized cell line that maintains the endothelial cell phenotype, including the response to specific regulators (such as VEGF), throughout extended replication times without signs of senescence and genetic instability [20]. We confirmed the adequacy of BUVEC-E6E7 by obtaining similar findings in primary cultures of human umbilical vein endothelial cells (HUVEC), the most frequently used in vitro model in oncology or cardiovascular endothelial cell research [31]. Like in BUVEC-E6E7, the CM from B16-F10 melanoma cells decreased the TEER of HUVEC monolayers and such reduction was prevented by VIAN-c4551, whereas VIAN-c4551 alone had no effect (Fig 4f). Furthermore, VIAN-c4551 prevented the decrease of TEER induced by the CM from a highly metastatic human breast cancer cell line (MDA-MB-231) [32], while the CM from a low-metastatic breast cancer cell line (MCF-7) [32,33] did not modify the TEER in HUVEC.

Fig 4. VIAN-c4551 inhibits the melanoma cell-induced permeability of endothelial cell monolayers mediated by VEGF.

Fig 4

Open in a new tab

(a) Effect of B16-F10 cells on the transendothelial electrical resistance (TEER) of bovine umbilical vein endothelial cell line (BUVEC-E6E7) monolayers in the absence or presence of VIAN-c4551 or anti-VEGF over a 6-hour period. *P = 0.0168, **P = 0.0081 vs Veh. (b) Effect of B16-F10 conditioned media (B16-F10-CM) on TEER of BUVEC-E6E7 monolayers. *P = 0.0182 vs Veh. (Repeated measurements one-way ANOVA, Dunnett’s multiple comparisons test). Values are means ± SD of 3 independent experiments. (c) VEGF levels in the conditioned medium of B16-F10 melanoma cells treated or not with VIAN-c4551 throughout a 24-hour incubation period. Values are means ± SD of 3 independent experiments. (d) Representative images of the actin cytoskeleton distribution in BUVEC-E6E7 monolayers treated or not with B16-F10-CM in the absence or presence of VIAN-c4551 or anti-VEGF (scale = 100 μm). (e) Effect of 3T3 conditioned media (3T3-CM) and B16-F10 conditioned media (B16-F10-CM) on TEER of BUVEC-E6E7 monolayers. *P = 0.0105 vs Veh. (Repeated measurements one-way ANOVA, Dunnett’s multiple comparisons test). (f) Effect of B16-F10 (B16-F10-CM), MDA-MB-231 (MDA-MB-231-CM), and MCF-7 (MCF-7-CM) conditioned media on TEER of human umbilical vein endothelial cell (HUVEC) monolayers. *P < 0.001 vs Veh. (Two-way ANOVA, Dunnett’s multiple comparisons test). Values are means ± SD of 3 independent experiments.

These findings supported the inhibition by VIAN-c4551 of VEGF-mediated endothelial cell permeability in response to melanoma cells and other metastatic cancer cells and encouraged investigating whether this action interfered with the ability of B16-F10 cells to extravasate.

VIAN-c4551 inhibits the transendothelial migration of B16-F10 cells in vitro and in vivo

The effect of VIAN-c4551 on the extravasation of melanoma cells was evaluated in vitro by measuring the migration of melanoma cells across a tight BUVEC-E6E7 monolayer. In this assay, fluorescent B16-F10-GFP cells were seeded at the top (luminal side) of a BUVEC-E6E7 confluent monolayer and the number of fluorescent cells found at the bottom (abluminal side) of the monolayer indicated transendothelial tumor cell migration. VIAN-c4551 reduced by 54% the number of B16-F10-GFP cells crossing the endothelial cell monolayer (Fig 5a and b), thereby supporting the inhibition of tumor cell extravasation by VIAN-c4551. Extravasation of melanoma cells was also studied in vivo. Mice were injected i.v. with VIAN-c4551 or vehicle (saline) 30 minutes before the i.v. inoculation of B16-F10-GFP and 2 hours later, mice were perfused and lungs collected to visualize tumor cell extravasation in the premetastatic lung through the histological presence of fluorescent tumor cells (Fig 5c) or the mRNA expression levels of GFP (Fig 5d). VIAN-c4551-treated mice demonstrated lower numbers of fluorescent tumor cells and reduced lung expression of GFP relative to controls.

Fig 5. VIAN-c4551 reduces the in vitro transendothelial migration and the lung extravasation of B16-F10 melanoma cells.

Fig 5

Open in a new tab

(a) Representative images showing the B16-F10 cells expressing GFP that migrated across a confluent endothelial cell monolayer in the presence of vehicle (Veh) or VIAN-c4551. (b) Quantification of the number of migrated B16-F10-GFP cells. Values are box and whiskers plot from 4 independent experiments. The mean is indicated by +. **P = 0.0042 vs Veh (unpaired t-test) (scale = 120 μm). (c) Representative lung sections showing extravasated B16-F10-GFP cells 2 hours after their inoculation (arrows) (scale = 100 μm). (d) GFP mRNA levels in lungs from Veh- and VIAN-c4551-treated mice. Values are box and whiskers plot from 2 independent experiments (n = 6). The mean is indicated by +. **P = 0.0014 vs Veh (unpaired t-test).

Subacute toxicity evaluation of VIAN-c4551

Due to its therapeutic potential, we performed a sub-acute toxicity study in mice daily injected i.v. with 2 doses of VIAN-c4551 for 14 days. No significant changes were observed in body weight, biochemical, and hematological parameters at either dose (Tables 1 and 2). Likewise, the weight of body organs such as the heart, lungs, liver, spleen and kidneys were similar among groups, and the histopathological examination of these organs revealed regular parenchyma architecture (data not shown).

Table 1. Body weight and serum biochemical parameters of mice treated with VIAN-c4551 i.v. for 14 days. Data are expressed as mean (SD), n = 6. One way ANOVA. i.v., intravenous; BW, body weight; Cr, creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Glu, glucose; ALB, albumin; TP, total protein. Reference values were from Charles River Technical Information Sheet for C57BL6/J mice [34], except for Urea [35] and Glu [36].

Parameters Reference values Vehicle VIAN-c4551
1 mg/kg/d		 VIAN-c4551
10 mg/kg/d		 P
BW (g) 16.70 - 20.10 16.59 (1.04) 17.47 (1.02) 16.97 (0.89) 0.50
Cr (mg/dl) 0.20 - 0.50 0.36 (0.02) 0.35 (0.02) 0.34 (0.02) 0.15
Urea (mmol/l) 9.27 - 12.09 9.75 (0.78) 10.14 (0.99) 9.34 (0.98) 0.26
ALT (IU/l) 27 - 195 67.17 (31.19) 57.60 (35.44) 84.33 (73.19) 0.29
AST (IU/l) 43 - 397 228 (55.57) 224.6 (110.23) 250.83 (54.1) 0.80
Glu (mmol/l) 4.59 - 9.89 6.20 (2.65) 7.49 (1.24) 6.30 (1.03) 0.58
ALB (g/dl) 2.40 - 4.30 3.30 (0.24) 3.42 (0.16) 3.46 (0.25) 0.16
TP (g/dl) 4.80 - 7.20 5.93 (0.72) 5.90 (0.21) 5.93 (0.46) 0.98
Open in a new tab

Table 2. Hematological parameters of mice treated with VIAN-c4551 i.v. for 14 days. Data are expressed as mean (SD), n = 6. One way ANOVA. HCT, hematocrit; Hb, hemoglobin; RBC, red blood cells; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; WBC, white blood cells; NEUT, neutrophils; LYM, lymphocytes; MON, monocytes. Reference values were from Charles River Technical Information Sheet for C57BL6/J mice [34], except for MON [36].

Parameters Reference values Vehicle VIAN-c4551
1 mg/kg/d		 VIAN-c4551
10 mg/kg/d		 P
HCT (%) 37.20 - 58.00 47 (4) 49 (4) 48 (2) 0.85
Hb (g/dl) 10.90 - 18.10 14.90 (1.19) 15.31 (1.17) 15.11 (0.57) 0.78
RBC (x1012/l) 7.37 - 11.50 10.35 (0.94) 10.65 (1.01) 10.47 (0.45) 0.90
MCV (fl) 42.60 - 55.60 45.73 (0.99) 45.70 (1.12) 45.58 (0.67) 0.89
MCHC (g/dl) 26.00 - 35.90 31.35 (0.32) 31.38 (3.19) 31.58 (5.60) 0.74
WBC (x109/l) 3.90 - 13.94 6.63 (1.56) 6.77 (2.78) 5.57 (1.20) 0.37
NEUT (x109/l) 0.42 - 2.55 2.12 (1.67) 1.40 (0.98) 1.07 (0.86) 0.32
LYM (x109/l) 2.88 - 10.92 4.45 (1.98) 5.32 (2.59) 4.48 (1.56) 0.74
MON (x109/l) 0.02 - 0.04 0.05 (0.08) 0.03 (0.05) 0.07 (0.08) 0.61
Open in a new tab

Data are expressed as mean (SD), n = 6. One way ANOVA. HCT, hematocrit; Hb, hemoglobin; RBC, red blood cells; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; WBC, white blood cells; NEUT, neutrophils; LYM, lymphocytes; MON, monocytes. Reference values were from Charles River Technical Information Sheet for C57BL6/J mice, except for MON [36].

Discussion

Metastasis is divided into pre-metastatic and post-metastatic phases that depend on whether tumor cells have or not engrafted at the metastatic region [2]. Because metastasis from a primary tumor can occur before primary cancer is detected [37], there is an urgent need to understand and target the premetastatic process involving the local invasion and intravasation of tumor cells at the primary site and their extravasation in remote organs [1,2]. Notably, primary tumors stimulate extravasation by increasing the permeability of blood vessels at metastatic sites [2,3,25,38,39]. Here, we support the inhibition of distant vascular permeability for the prevention of tumor metastasis and unveil the anti-vasopermeability factor VIAN-c4551 as a potential therapeutic drug able to prevent metastasis generation.

Melanoma (B16-F10) and breast (MDA-MB-231) cancer cell lines increase the permeability of lung blood vessels before metastasis by the production of vasoactive factors such as angiopoietin (Angpt) 2 and 4, matrix metalloproteinases (MMP) 1, 2, 3, and 10 and downstream effectors of VEGF (epiregulin and cyclooxygenase 2). These factors increase the permeability of lung capillaries that facilitates the transendothelial passage of tumor cells to seed pulmonary metastases [25,38,39]. Because increased vascular permeability favors extravasation, an essential step in pre-metastatic progression, inhibitors of vasopermeability represent promising therapeutics. One such inhibitor is VIAN-c4551, the cyclic heptapeptide analog of the endogenous anti-angiogenic protein vasoinhibin.

Vasoinhibin inhibits the increase in vascular permeability induced by VEGF by promoting the dephosphorylation/inactivation of endothelial nitric oxide synthase (eNOS) leading to the inhibition of the production of nitric oxide [40], an important signal that destabilizes the endothelial cell barrier through posttranslational modifications of adherent junction proteins [41]. VIAN-c4551 also inhibits the VEGF-induced permeability of endothelial cell monolayers [19] and both VIAN-c4551 [19] and vasoinhibin [40,42] protect against disruption of the blood retinal barrier in experimental models of diabetic retinopathy. However, beneficial effects against the extravasation of premetastatic tumors remain to be determined.

In our study, we inoculated B16-F10 cells into the tail vein of mice to circumvent primary tumor formation with the advantage of establishing a correlation between short-term lung hypervasopermeability and rapid metastatic progression. We showed that melanoma cells maximally increase pulmonary vascular permeability and extravasate at 2 hours post inoculation and that hypervasopermeability lasted at least 8 hours. The timing is consistent with the reported 8 hours required for melanoma cells to extravasate after their systemic delivery [26] and, thereby, with their metastatic seeding. Furthermore, enhanced vasopermeability at 2 hours associated with the upregulation of circulating VEGF levels suggesting the release of VEGF by melanoma cells as responsible mechanism. Accordingly, we hypothesized that the acute treatment with a VEGF inhibitor such as VIAN-c4551 would block the increase in lung vascular permeability and interfere with the extravasation process leading to fewer pulmonary metastasis. In agreement, a single intravascular injection of VIAN-c4551 inhibited the early increase in lung vasopermeability and the extravasation of melanoma cells and was enough to substantially reduce the number and size of macroscopic and microscopic metastatic nodules in lungs.

Inhibition of lung vascular leakage was previously reported to limit the number of B16-F10 cells exiting the circulation and their metastatic spread [25]. However, in contrast to our study, vasopermeability was evaluated in the presence of the primary melanoma tumor and after longer times (days) following B16-F10 cell intravascular inoculation. The authors proposed as a mechanism the altered lung microenvironment by the primary tumor through the local expression of vasopermeability factors, namely Angpt 2, MMP3, and MMP10, but not VEGF [25]. However, VEGF circulating levels were not evaluated.

The contribution of systemic VEGF to tumor cell extravasation is consistent with circulating cancer cells producing VEGF that is directly related to their metastatic potential [43] and with highly metastatic cancer cells circulating as multicellular clusters [44] whose extravasation is favored by vascular leakage. Also, the VEGF inhibitor VIAN-c4551 blocked melanoma cell-induced lung vasopermeability, melanoma cell extravasation, and metastatic growth. By comparing the vasopermeability effect on TEER values of B16-F10 cells to that of non-metastatic cells (3T3 cells) or breast cancer cells with low (MCF7) and high (MDA-MB-231) metastatic potential, our in vitro data supported the functional link between increased vasopermeability and metastatic activity and extended the putative anti-metastatic influence of VIAN-c4551 to other types of cancer. Moreover, our in vitro findings showed that VEGF secreted by B16-F10 cells perturbs endothelial cell junctions in a manner that facilitates the passage of tumor cells across endothelial cell monolayers and that VIAN-c4551 prevented melanoma cell-induced vascular leakage like the anti-VEGF antibody fragment ranibizumab, which blocks the interaction of VEGF with its receptor [45]. Of note, VIAN-c4551 did not reduce the upregulation of VEGF circulating levels following melanoma cell inoculation nor the release of VEGF by cultured melanoma cells indicating that VIAN-c4551 targets the action and not the production of VEGF.

Our study does not rule out that other vasopermeability factors produced by melanoma cells are targeted by VIAN-c4551. Vasoinhibin is a broad acting agent that inhibits the action of different vasoactive factors [5]. It binds to a multi-protein complex that includes plasminogen activator inhibitor 1 (PAI-1), urokinase, and the urokinase receptor [46] in endothelial cell membranes which can contribute to the inhibition of multiple signaling pathways (Ras-Raf-MAPK, Ras-Tiam1-Rac1-Pak1, PI3K-Akt-eNOS, and PLCγ-eNOS) activated by several proangiogenic and vasopermeability factors (VEGF, basic fibroblast growth factor, bradykinin, and interleukin-1β) [5]. It is unclear how binding to the multi-protein complex inhibits endothelial cells angiogenic processes [46], and the contribution of other vasoinhibin-binding proteins [47] and/or interacting molecules [48] likely participate. Along this line, VIAN-c4551 does not bind to PAI-1 [49], yet it inhibits VEGF-induced vasopermeability [19; present results] and blood vessel growth [4].

Vasoinhibin reduces vascular leakage by blocking the phosphorylation/activation and the calcium-calmodulin binding/activation of eNOS in response to VEGF, bradykinin, acetylcholine, diabetic vitreous, and arthritic joints [40,42,50,51]. Likewise, vasoinhibin inhibits the action of several proangiogenic factors (VEGF, bFGF, bradykinin, IL-1β) with an impact on angiogenesis-dependent diseases, including cancer [5,12]. In fact, there is evidence that vasoinhibin inhibits the growth and vascularization of melanoma metastatic nodules in lungs during the post-metastatic phase [16], i.e., after pulmonary engraftment and colonization [1,26]. In that study [16], an adenoviral vector encoding the vasoinhibin isoform of 16 kDa (16k PRL) delivered 2 days post-melanoma cell intravascular inoculation, reduced the number and size of lung metastases. The tardy 2-day treatment and the delayed upregulation of vasoinhibin by gene therapy precluded evaluating the influence of vasoinhibin at the pre-metastatic phase.

A major obstacle for addressing vasoinhibin action in animal models has been the lack of sufficient functional protein. Post-translational modifications, protein folding, and instability complicate the recombinant production of vasoinhibin [18] and the delivery of sufficient quantities of vasoinhibin needed the gene therapy approach [16,52]. These difficulties have been overcome by the development of VIAN-c4551, a potent, easy-to-produce vasoinhibin analog [4]. VIAN-c4551 uncovered inhibition of vascular leakage as a novel mechanism by which vasoinhibin could block cancer cell extravasation at the pre-metastatic phase. However, the effect may be stronger in VIAN-c4551 because it lacks the ability of vasoinhibin to upregulate adhesion molecules in endothelial cells [49,53] that favor melanoma-endothelial cell interaction for extravasation [54]. Furthermore, VIAN-c4551 may be regarded as safe as it did not cause any significant change in hematological, biochemical, and histological parameters in our sub-acute toxicity study.

In conclusion, our in vitro and in vivo studies support vascular leakage as a limiting step for cancer cell extravasation and disclose VIAN-c4551 as a potential anti-cancer agent for the early prevention of metastatic spread that warrants further research.

Acknowledgments

The authors thank Fernando López Barrera, Xarubet Ruíz Herrera, Adriana González Gallardo, Ericka A. de los Ríos Arellano, Nydia Hernández Ríos, Moisés Mendoza Baltazar, Alejandra Castilla León, María A. Carbajo Mata, Eugenia Ramos Aguilar, and Martín García Servín for their excellent technical assistance.

Data Availability

All relevant data are within the paper and its Supporting Information files

Funding Statement

This work was supported by the Dirección General de Asuntos del Personal Académico (DGAPA) Universidad Nacional Autónoma de México (UNAM) (Grant IN202424) to CC. Alma Lorena Perez is a doctoral student from the ‘Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM)’ and has received fellowship 788879 from Consejo Nacional de Humanidades, Ciencia y Tecnología (CONAHCYT). MZ, EA-C, and JPR are postdoctoral fellows from CONAHCYT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, Hall JA, et al. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol. 2019;16(3):185–204. doi: 10.1038/s41571-018-0134-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tomita T, Kato M, Hiratsuka S. Regulation of vascular permeability in cancer metastasis. Cancer Sci. 2021;112(8):2966–74. doi: 10.1111/cas.14942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Li X, Padhan N, Sjöström EO, Roche FP, Testini C, Honkura N, et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat Commun. 2016;7:11017. doi: 10.1038/ncomms11017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Robles JP, Zamora M, Siqueiros-Marquez L, Adan-Castro E, Ramirez-Hernandez G, Nuñez FF, et al. The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide. Angiogenesis. 2022;25(1):57–70. doi: 10.1007/s10456-021-09800-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Clapp C, Thebault S, Macotela Y, Moreno-Carranza B, Triebel J, Martínez de la Escalera G. Regulation of blood vessels by prolactin and vasoinhibins. Adv Exp Med Biol. 2015;846:83–95. doi: 10.1007/978-3-319-12114-7_4 [DOI] [PubMed] [Google Scholar]
  • 6.Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, López-Barrera F, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci. 2005;46(8):2947–53. doi: 10.1167/iovs.05-0173 [DOI] [PubMed] [Google Scholar]
  • 7.Macotela Y, Aguilar M, Guzmán-Morales J, Rivera J, Zermeño C, López-Barrera F. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci. 2006;119(9):1790–800. [DOI] [PubMed] [Google Scholar]
  • 8.Triebel J, Bertsch T, Clapp C. Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited. Front Endocrinol. 2022;13(9):994898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Clapp C, Ortiz G, García-Rodrigo JF, Ledesma-Colunga MG, Martínez-Díaz OF, Adán N, et al. Dual Roles of Prolactin and Vasoinhibin in Inflammatory Arthritis. Front Endocrinol (Lausanne). 2022;13:905756. doi: 10.3389/fendo.2022.905756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600. doi: 10.1016/j.cell.2007.01.003 [DOI] [PubMed] [Google Scholar]
  • 11.González C, Parra A, Ramírez-Peredo J, García C, Rivera JC, Macotela Y, et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest. 2007;87(10):1009–17. doi: 10.1038/labinvest.3700662 [DOI] [PubMed] [Google Scholar]
  • 12.Clapp C, Thebault S, Jeziorski MC, Martínez De La Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev. 2009;89(4):1177–215. doi: 10.1152/physrev.00024.2009 [DOI] [PubMed] [Google Scholar]
  • 13.Kim J, Luo W, Chen D-T, Earley K, Tunstead J, Yu-Lee L-Y, et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 2003;63(2):386–93. [PubMed] [Google Scholar]
  • 14.Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res. 2001;61(19):7356–62. [PubMed] [Google Scholar]
  • 15.Faupel-Badger JM, Ginsburg E, Fleming JM, Susser L, Doucet T, Vonderhaar BK. 16 kDa prolactin reduces angiogenesis, but not growth of human breast cancer tumors in vivo. Horm Cancer. 2010;1(2):71–9. doi: 10.1007/s12672-010-0012-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Nguyen N-Q-N, Cornet A, Blacher S, Tabruyn SP, Foidart J-M, Noël A, et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther. 2007;15(12):2094–100. doi: 10.1038/sj.mt.6300294 [DOI] [PubMed] [Google Scholar]
  • 17.Kinet V, Nguyen N, Sabatel C, Blacher S, Noël A, Martial J. Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Lett. 2009;284(2):222–8. [DOI] [PubMed] [Google Scholar]
  • 18.Moreno-Carranza B, Robles JP, Cruces-Solís H, Ferrer-Ríos MG, Aguilar-Rivera E, Yupanki M, et al. Sequence optimization and glycosylation of vasoinhibin: Pitfalls of recombinant production. Protein Expr Purif. 2019;161:49–56. doi: 10.1016/j.pep.2019.04.011 [DOI] [PubMed] [Google Scholar]
  • 19.Adán-Castro E, Zamora M, Granados-Carrasco D, Siqueiros-Márquez L, García-Rodrigo J, Bertsch T. Topical ophthalmic administration of vian-c4551 antiangiogenic peptide for diabetic macular edema: preclinical efficacy and ocular pharmacokinetics. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.09.11.612517v1 [Google Scholar]
  • 20.Cajero-Juárez M, Avila B, Ochoa A, Garrido-Guerrero E, Varela-Echavarría A, Martínez de la Escalera G, et al. Immortalization of bovine umbilical vein endothelial cells: a model for the study of vascular endothelium. Eur J Cell Biol. 2002;81(1):1–8. doi: 10.1078/0171-9335-00213 [DOI] [PubMed] [Google Scholar]
  • 21.Baudin B, Bruneel A, Bosselut N, Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc. 2007;2(3):481–5. doi: 10.1038/nprot.2007.54 [DOI] [PubMed] [Google Scholar]
  • 22.Robles JP, Zamora M, Adan-Castro E, Siqueiros-Marquez L, Martinez de la Escalera G, Clapp C. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling. J Biol Chem. 2022;298(3):101695. doi: 10.1016/j.jbc.2022.101695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Adán-Castro E, Siqueiros-Márquez L, Ramírez-Hernández G, Díaz-Lezama N, Ruíz-Herrera X, Núñez FF, et al. Sulpiride-induced hyperprolactinaemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats. J Neuroendocrinol. 2022;34(4):e13091. doi: 10.1111/jne.13091 [DOI] [PubMed] [Google Scholar]
  • 24.Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol. 2001;Chapter 20:Unit 20.1. doi: 10.1002/0471142735.im2001s39 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Huang Y, Song N, Ding Y, Yuan S, Li X, Cai H, et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 2009;69(19):7529–37. doi: 10.1158/0008-5472.CAN-08-4382 [DOI] [PubMed] [Google Scholar]
  • 26.Chambers A, Schmidt E, MacDonald I, Morris V, Groom A. Early steps in hematogenous metastasis of B16F1 melanoma cells in chick embryos studied by high-resolution intravital videomicroscopy. J Natl Cancer Inst. 1992;84(10):797–803. [DOI] [PubMed] [Google Scholar]
  • 27.Srinivasan B, Kolli A, Esch M, Abaci H, Shuler M, Hickman J. Teer measurement techniques for in vitro barrier model systems. SLAS Technol. 2015;20(2):107–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Amado-Azevedo J, de Menezes RX, van Nieuw Amerongen GP, van Hinsbergh VWM, Hordijk PL. A functional siRNA screen identifies RhoGTPase-associated genes involved in thrombin-induced endothelial permeability. PLoS One. 2018;13(7):e0201231. doi: 10.1371/journal.pone.0201231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8(11):1223–34. doi: 10.1038/ncb1486 [DOI] [PubMed] [Google Scholar]
  • 30.Bradley MO, Kraynak AR, Storer RD, Gibbs JB. Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes. Proc Natl Acad Sci U S A. 1986;83(14):5277–81. doi: 10.1073/pnas.83.14.5277 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Majewska A, Wilkus K, Brodaczewska K, Kieda C. Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies. Int J Mol Sci. 2021;22(2):520. doi: 10.3390/ijms22020520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Phannasil P, Akekawatchai C, Jitrapakdee S. MicroRNA expression profiles associated with the metastatic ability of MDA‑MB‑231 breast cancer cells. Oncol Lett. 2023;26(2):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Comşa Ş, Cîmpean AM, Raica M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Res. 2015;35(6):3147–54. [PubMed] [Google Scholar]
  • 34.Charles R. Technical Information Sheet of C57BL/6 Mouse Model. [Internet]. Wilmington, MA, USA. Charles River Laboratories; [updated 2019; cited 2025 Mar 27] Available from: https://www.criver.com/products-services/find-model/c57bl6-mouse [Google Scholar]
  • 35.Otto GP, Rathkolb B, Oestereicher MA, Lengger CJ, Moerth C, Micklich K, et al. Clinical chemistry reference intervals for C57BL/6J, C57BL/6N, and C3HeB/FeJ mice (Mus musculus). J Am Assoc Lab Anim Sci. 2016;55(4):375–86. [PMC free article] [PubMed] [Google Scholar]
  • 36.Coman C, Vlase E, Dinu A. Hematological and plasma biochemical values in four specific pathogen-free mice strains produced in the animal facility at Cantacuzino Institute, Bucharest. Sci Works Ser C Vet Med. 2018;LXIV(1):115–22. [Google Scholar]
  • 37.Friberg S, Nyström A. Cancer Metastases: Early Dissemination and Late Recurrences. Cancer Growth Metastasis. 2015;8:43–9. doi: 10.4137/CGM.S31244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Padua D, Zhang X, Wang Q, Nadal C, Gerald W, Gomis R. Tgfβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007;446(7137):765–70. doi: 10.1038/nature05760 [DOI] [PubMed] [Google Scholar]
  • 40.García C, Aranda J, Arnold E, Thébault S, Macotela Y, López-Casillas F. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A–dependent eNOS inactivation. J Clin Invest. 2008;118(6):2291–300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Thibeault S, Rautureau Y, Oubaha M, Faubert D, Wilkes BC, Delisle C, et al. S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. Mol Cell. 2010;39(3):468–76. doi: 10.1016/j.molcel.2010.07.013 [DOI] [PubMed] [Google Scholar]
  • 42.Arredondo Zamarripa D, Díaz-Lezama N, Meléndez García R, Chávez Balderas J, Adán N, Ledesma-Colunga MG, et al. Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress. Front Cell Neurosci. 2014;8:333. doi: 10.3389/fncel.2014.00333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, et al. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2009;11(6):R84. doi: 10.1186/bcr2452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Allen TA, Asad D, Amu E, Hensley MT, Cores J, Vandergriff A, et al. Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential. J Cell Sci. 2019. Sep 9;132(17):jcs231563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Chen Y, Han F. Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Ther Clin Risk Manag. 2012. Jul 11;8:343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bajou K, Herkenne S, Thijssen VL, D’Amico S, Nguyen N-Q-N, Bouché A, et al. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat Med. 2014;20(7):741–7. doi: 10.1038/nm.3552 [DOI] [PubMed] [Google Scholar]
  • 47.Clapp C, Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology. 1992;130(3):1380–6. doi: 10.1210/endo.130.3.1311239 [DOI] [PubMed] [Google Scholar]
  • 48.Morohoshi K, Mochinaga R, Watanabe T, Nakajima R, Harigaya T. 16 kDa vasoinhibin binds to integrin alpha5 beta1 on endothelial cells to induce apoptosis. Endocr Connect. 2018;7(5):630–6. doi: 10.1530/EC-18-0116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Robles JP, Zamora M, Garcia-Rodrigo JF, Perez AL, Bertsch T, Martinez de la Escalera G, et al. Vasoinhibin’s Apoptotic, Inflammatory, and Fibrinolytic Actions Are in a Motif Different From Its Antiangiogenic HGR Motif. Endocrinology. 2023;165(2):bqad185. doi: 10.1210/endocr/bqad185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology. 2004;145(12):5714–22. doi: 10.1210/en.2004-0647 [DOI] [PubMed] [Google Scholar]
  • 51.Ortiz G, Ledesma-Colunga MG, Wu Z, García-Rodrigo JF, Adan N, Martínez de la Escalera G, et al. Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis. Lab Invest. 2020;100(8):1068–79. doi: 10.1038/s41374-020-0432-5 [DOI] [PubMed] [Google Scholar]
  • 52.Ramírez M, Wu Z, Moreno-Carranza B, Jeziorski M, Arnold E, Díaz-Lezama N, et al. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against vegf- and diabetes-induced retinal vasopermeability. Invest Ophthalmol Vis Sci. 2011;52(12):8944–50. [DOI] [PubMed] [Google Scholar]
  • 53.Tabruyn SP, Sabatel C, Nguyen N-Q-N, Verhaeghe C, Castermans K, Malvaux L, et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Mol Endocrinol. 2007;21(6):1422–9. doi: 10.1210/me.2007-0021 [DOI] [PubMed] [Google Scholar]
  • 54.Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. Lfa-1 and icam-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC Cancer. 2012;12:455. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Mohamed Abdelkarim

31 Jan 2025

PONE-D-24-58885The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeabilityPLOS ONE

Dear Dr. Clapp,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 17 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Mohamed Abdelkarim

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1.  Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf   and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“This work was supported by the Dirección General de Asuntos del Personal Académico (DGAPA) Universidad Nacional Autónoma de México (UNAM) (Grant IN202424) to CC. Alma Lorena Perez is a doctoral student from the ‘Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM)’ and has received fellowship 788879 from Consejo Nacional de Humanidades, Ciencia y Tecnología (CONAHCYT). MZ, EA-C and JPR are postdoctoral fellows from CONAHCYT.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. We note that you have a patent relating to material pertinent to this article. Please provide an amended statement of Competing Interests to declare this patent (with details including name and number), along with any other relevant declarations relating to employment, consultancy, patents, products in development or modified products etc. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

This information should be included in your cover letter; we will change the online submission form on your behalf.

4. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript by Perez et al, the authors investigated the function of VIAN-c4551, a peptide analogue of vasoinhibin, in extravasation and lung metastasis of melanoma cells. They discovered that VIAN-c4551 inhibits B16-F10 cell-induced increase in vascular permeability and metastasis in vivo, as well as endothelial monolayer permeability in vitro. This is a well-designed study. However, there are a number of concerns that need to be addressed before this manuscript is in a publishable fashion. Specific comments are as follows:

1) In the Evans blue assay, the quantified data were shown as the dye concentration in the extracts (as described in the Methods). The unit is ul/ g lung x h. What the "ul" represents needs to be defined.

2) Is there a particular reason that female animals were used in this study?

3) Although TEER and transendothelial migration assays are established methods. It is advised to put in more details on for example, how to define BUVEC-E6E7 monolayers.

4) Do non-metastatic cancer cells (and their conditioned medium) affect TEER as there is no control for this part?

5) In the discussion, in Line 336, the authors stated that VIAN-c4551 inhibits the increase in vascular permeability induced by VEGF by blocking production of NO by eNOS. Is it shown in ref. 19? Please rephrase if it is not a published result.

6) The results show that VIAN-c4551 blocks metastatic cell-induced increase in vascular permeability, presumably through suppressing VEGF action without affecting VEGF expression. So how does this work? As this manuscript does not have data for mechanistic investigation, the authors should at least discuss potential molecular mechanisms such as putative receptors, signaling pathways, distinct features from vasoinhibin etc.

7) Minor: a number of typos: line 90 - SFB; line 158 - lung paraffin sections from lungs

Reviewer #2: The study titled “The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability” demonstrates that VIAN-c4551 effectively inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability and preventing melanoma cell extravasation. The findings are well-supported by both in vivo and in vitro experiments, and the study opens new avenues for the development of anti-metastatic therapies. However, further research is needed to validate these findings in human clinical trials and to explore the full range of mechanisms by which VIAN-c4551 exerts its anti-metastatic effects.

To further evaluate the study’s findings and address potential limitations, the following questions could be posed to the authors:

Dose Selection and Optimization:

- Why was a single dose of VIAN-c4551 (1 mg/kg) chosen for the experiments? Have you conducted dose-response studies to determine the optimal therapeutic dose?

- Have you explored the pharmacokinetics of VIAN-c4551, such as its half-life, bioavailability, or potential accumulation in tissues, which could influence its efficacy and safety?

Toxicity and Safety:

- Did you evaluate the potential toxicity of VIAN-c4551 in mice, particularly with long-term administration? Were there any signs of systemic toxicity, such as organ damage or immune suppression?

- Why did you not assess other serum markers (e.g., liver enzymes, kidney function) to evaluate the systemic impact of VIAN-c4551 treatment?

In Vitro Model Selection:

- Why did you choose bovine umbilical vein endothelial cells (BUVEC-E6E7) for the in vitro experiments? Did you consider using human endothelial cell lines to better reflect human physiology?

- Why did you focus on venous endothelial cells rather than arterial endothelial cells, which might be more relevant to the pulmonary vasculature and metastatic seeding?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Plos one report.docx

pone.0316983.s001.docx (15.6KB, docx)
PLoS One. 2025 May 28;20(5):e0316983. doi: 10.1371/journal.pone.0316983.r003

Author response to Decision Letter 0

4 Apr 2025

Reviewer 1:

In this manuscript by Perez et al, the authors investigated the function of VIAN-c4551, a peptide analogue of vasoinhibin, in extravasation and lung metastasis of melanoma cells. They discovered that VIAN-c4551 inhibits B16-F10 cell-induced increase in vascular permeability and metastasis in vivo, as well as endothelial monolayer permeability in vitro. This is a well-designed study.

However, there are a number of concerns that need to be addressed before this manuscript is in a publishable fashion.

Reply: We thank the reviewer for the kind comments and careful evaluation of our work.

Specific comments are as follows:

1) In the Evans blue assay, the quantified data were shown as the dye concentration in the extracts (as described in the Methods). The unit is ul/ g lung x h. What the "ul" represents needs to be defined.

Reply: µl indicates the volume of extravasated plasma in lungs. We have clarified this information by modifying the legend of the Y axis in Figures 1c and 2c to “µl plasma /g lung dry weight x h”.

2) Is there a particular reason that female animals were used in this study?

Reply: The preceding work showing the inhibition of melanoma tumor growth and neovascularization by vasoinhibin (Nguyen et al., 2007) and VIAN-c4551 (Robles et al., 2022) was performed in female adult C57/BL6 mice. Because the purpose of the current study was to investigate whether the anti-tumor action of VIAN-c4551 extended to the inhibition of melanoma cell extravasation, we continued using the female as working model. However, there are sex differences in melanoma tumor progression that may relate to a more robust immune system in females (Dakup et al., 2020). Addressing the anti-tumor action of VIAN-c4551 on both sexes warrants further research. The use of females has been explained in the revised text (lines 134-136).

3) Although TEER and transendothelial migration assays are established methods. It is advised to put in more details on for example, how to define BUVEC-E6E7 monolayers.

Reply: Descriptions were extended in the revised manuscript as follows:

Vascular permeability in vitro (lines 94-98):

BUVEC-E6E7 were seeded on 6.5 mm transwell clear polyester membrane inserts (Corning) with pore sizes of 0.4 μm at an initial density of 7.2 x 103 cells per well (30% confluency). After approximately 96 hours, transendothelial electrical resistance (TEER) measured by the EVOM2 Epithelial Voltohmmeter (World Precision Instruments, Sarasota, FL) stabilized around 55 Ω.cm2 (reflecting a confluent monolayer) and treatments started.

Transendothelial migration assay (lines 124-128):

BUVEC-E6E7 (7.2 x 103) were seeded on 6.5 mm transwell membrane inserts with 8 μm pores coated with 0.38 mg/ml matrigel (354234, Corning). Upon confluency (55 Ω.cm2, revealed by the EVOM2 resistance tester) monolayers were treated for 1 hour with 100 nM VIAN-c4551 into the upper (luminal) chamber followed by the addition of fluorescent B16-F10-GFP cells (3.5 x 104 cells per well).

4) Do non-metastatic cancer cells (and their conditioned medium) affect TEER as there is no control for this part?

Reply: Attending the reviewer’s concern, we now show that the NIH/3T3 mouse cell line derived from embryonic fibroblasts devoid of metastatic activity (Bradley et al., 1986) does not affect TEER. Their conditioned media (3T3-CM) did not modify the TEER of bovine umbilical vein endothelial cell (BUVEC-E6E7) monolayers throughout a 6-hour incubation period (new Figure 4e). We have also addressed this issue by showing that conditioned media (CM) from the highly metastatic human breast cancer cell line (MDA-MB-231) (Phannasil et al., 2023) decreased the TEER of primary human umbilical vein endothelial cell (HUVEC) monolayers to a similar level than the CM from B16F10 melanoma cells, whereas the CM from low metastatic human breast cancer cells (MCF7) (Comşa et al., 2015; Phannasil et al., 2023) had no effect (new Figure 4f). Notably, VIAN-c4551 prevented the reduction of the TEER induced by metastatic melanoma and breast cancer cells in HUVEC. These findings support the functional link between increased vasopermeability (TEER values) and metastatic activity, validate the experimental use of BUVEC-E6E7, and extend the potential anti-metastatic influence of VIAN-c4551 to other cancer cell types. The new figures and information have been included in the revised manuscript (new Figures 4e and 4f; lines 83-85; 102, 104-109, 306-320; 332-338; 340; 439-444).

5) In the discussion, in Line 336, the authors stated that VIAN-c4551 inhibits the increase in vascular permeability induced by VEGF by blocking production of NO by eNOS. Is it shown in ref. 19? Please rephrase if it is not a published result.

Reply: The information has been rephrased to clearly indicate corresponding published data. The corrected paragraph (Lines 406-413) is as follows: “Vasoinhibin inhibits the increase in vascular permeability induced by VEGF by promoting the dephosphorylation/inactivation of endothelial nitric oxide synthase (eNOS) leading to the inhibition of the production of nitric oxide (García et al., 2008), an important signal that destabilizes the endothelial cell barrier through posttranslational modifications of adherent junction proteins (Thibeault et al., 2010). VIAN-c4551 also inhibits the VEGF-induced permeability of endothelial cell monolayers (Adán-Castro et al., 2024) and both VIAN-c4551 (Adán-Castro et al., 2024) and vasoinhibin (Arredondo Zamarripa et al., 2014; García et al., 2008) protect against disruption of the blood retinal barrier in experimental models of diabetic retinopathy. However, beneficial effects against the extravasation of premetastatic tumors remain to be determined.”

6) The results show that VIAN-c4551 blocks metastatic cell-induced increase in vascular permeability, presumably through suppressing VEGF action without affecting VEGF expression. So how does this work? As this manuscript does not have data for mechanistic investigation, the authors should at least discuss potential molecular mechanisms such as putative receptors, signaling pathways, distinct features from vasoinhibin etc.

Reply: In attention to the reviewer’s request, we have described potential molecular mechanisms mediating the actions of VIAN-c4551 vs. those of vasoinhibin (Lines 453-461). Description is as follows: “Vasoinhibin binds to a multi-protein complex that includes plasminogen activator inhibitor 1 (PAI-1), urokinase, and the urokinase receptor (Bajou et al., 2014) in endothelial cell membranes which can contribute to the inhibition of multiple signaling pathways (Ras-Raf-MAPK, Ras-Tiam1-Rac1-Pak1, PI3K-Akt-eNOS, and PLCγ-eNOS) activated by several proangiogenic and vasopermeability factors (VEGF, basic fibroblast growth factor, bradykinin, and interleukin-1β) (Clapp et al., 2015). It is unclear how binding to the multi-protein complex inhibits endothelial cells angiogenic processes (Bajou et al., 2014) and the contribution of other vasoinhibin-binding proteins (Clapp & Weiner, 1992) and/or interacting molecules (Morohoshi et al., 2018) likely participate. Along this line, VIAN-c4551 does not bind to PAI-1 (Robles et al., 2023), yet it inhibits VEGF-induced vasopermeability (Adán-Castro et al., 2024; present results) and blood vessel growth (Robles et al., 2022).” The binding molecule/receptor transducing VIAN-c4551’s anti-vasopermeability and antiangiogenic properties are matter of ongoing investigation.

Minor: a number of typos: line 90 - SFB; line 158 - lung paraffin sections from lungs.

Reply: Corrected, thank you (lines 99 and 176-177).

Reviewer 2:

The study titled “The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability” demonstrates that VIAN-c4551 effectively inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability and preventing melanoma cell extravasation. The findings are well-supported by both in vivo and in vitro experiments, and the study opens new avenues for the development of anti-metastatic therapies. However, further research is needed to validate these findings in human clinical trials and to explore the full range of mechanisms by which VIAN-c4551 exerts its anti-metastatic effects.

To further evaluate the study’s findings and address potential limitations, the following questions could be posed to the authors:

Reply: We thank the reviewer for the kind comments and careful evaluation of our work.

Dose Selection and Optimization:

- Why was a single dose of VIAN-c4551 (1 mg/kg) chosen for the experiments? Have you conducted dose-response studies to determine the optimal therapeutic dose?

Reply: A previous study (Robles et al., 2022) showed that VIAN-c4551 (initially named CRIVi45-51) reduced the volume of subcutaneous melanoma tumors in a dose-related manner with 1 mg/kg being the more effective dose. This information has been added to the revised manuscript (Line 142-143).

- Have you explored the pharmacokinetics of VIAN-c4551, such as its half-life, bioavailability, or potential accumulation in tissues, which could influence its efficacy and safety?

- Did you evaluate the potential toxicity of VIAN-c4551 in mice, particularly with long-term administration? Were there any signs of systemic toxicity, such as organ damage or immune suppression?

- Why did you not assess other serum markers (e.g., liver enzymes, kidney function) to evaluate the systemic impact of VIAN-c4551 treatment

Reply: The purpose of our study was to investigate whether, by virtue of its anti-vasopermeability properties, VIAN-c4551 interfered with the extravasation of melanoma cells thereby blocking metastasis generation in mice. Exploring the pharmacokinetics and safety of VIAN-c4551 was beyond the scope of our work. However, in attention to the reviewer’s concern and considering that the findings of our work support the therapeutic potential of VIAN-c4551, we have performed an initial toxicity analysis in six female mice daily injected (i.v.) with vehicle (saline) or with a single dose of VIAN-c4551 (1 or 10 mg/kg) for 14 days. Changes in body weight, blood hematological parameters, serum biochemical parameters, and histopathology were analyzed at the end of the experiment. The two doses of VIAN-c4551 appeared safe as no detrimental effects were observed. These findings are included in the revised manuscript (Tables 1 and 2, Lines 37-39; 42; 199-208; 367-373; 482-484).

In Vitro Model Selection:

- Why did you choose bovine umbilical vein endothelial cells (BUVEC-E6E7) for the in vitro experiments? Did you consider using human endothelial cell lines to better reflect human physiology?

Reply: BUVEC-E6E7 is a well-characterized cell line that maintains the endothelial cell phenotype, including the response to specific regulators (such as VEGF), throughout extended replication times without signs of senescence and genetic instability (Cajero-Juárez et al., 2002). These advantages make BUVEC-E6E7 a good model with repeatable and comparable results. However, in attention to the reviewer’s consideration, we now provide data showing similar findings in primary cultures of human umbilical vein endothelial cells (HUVEC). Like in BUVEC-E6E7, the conditioned media from B16-F10 melanoma cells (B16-F10-CM) decreased the TEER of HUVEC monolayers, VIAN-c4551 prevented such reduction, and VIAN-c4551 alone had no effect (new Figure 4f). Furthermore, VIAN-c4551 prevented the decrease of TEER in HUVEC induced by the CM from a highly metastatic human breast cancer cell line (MDA-MB-231) (Phannasil et al., 2023). These results extend the findings in BUVEC-E6E7 to primary cultures of human endothelial cells (HUVEC) and the potential anti-metastatic influence of VIAN-c4551 to other cancer cell types. (new Figure 4f; lines 89-92; 104-109; 312-320; 334-338).

- Why did you focus on venous endothelial cells rather than arterial endothelial cells, which might be more relevant to the pulmonary vasculature and metastatic seeding?

Reply: Umbilical vein endothelial cells of human origin have been the most frequently used in vitro model in oncology or cardiovascular endothelial cell research (Majewska et al., 2021). Because donor heterogeneity and short-term cultures limit their use, we turned to the immortalized endothelial cell line BUVEC-E6E7. However, we agree with the reviewer that the heterogeneity of endothelial cells in different tissues plays a role in pathophysiology, although the preservation of such differences is challenged in vitro (Majewska et al., 2021). The current study attempted to circumvent in vitro limitations by the in vivo analysis. Nonetheless, the use of lung capillary endothelial cells warrants further research. Part of this information has been added to the revised manuscript (lines 310-315)

References

Adán-Castro, E., Zamora, M., Granados-Carrasco, D., Siqueiros-Márquez, L., García-Rodrigo, J. F., Bertsch, T., Triebel, J., Escalera, G. M. de la, Robles, J. P., & Clapp, C. (2024). Topical Ophthalmic Administration of VIAN-c4551 Antiangiogenic Peptide for Diabetic Macular Edema: Preclinical Efficacy and Ocular Pharmacokinetics (p. 2024.09.11.612517). bioRxiv. https://doi.org/10.1101/2024.09.11.612517

Arredondo Zamarripa, D., Díaz-Lezama, N., Meléndez García, R., Chávez Balderas, J., Adán, N., Ledesma-Colunga, M. G., Arnold, E., Clapp, C., & Thebault, S. (2014). Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress. Frontiers in Cellular Neuroscience, 8, 333. https://doi.org/10.3389/fncel.2014.00333

Bajou, K., Herkenne, S., Thijssen, V. L., D’Amico, S., Nguyen, N.-Q.-N., Bouché, A., Tabruyn, S., Srahna, M., Carabin, J.-Y., Nivelles, O., Paques, C., Cornelissen, I., Lion, M., Noel, A., Gils, A., Vinckier, S., Declerck, P. J., Griffioen, A. W., Dewerchin, M., … Struman, I. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, 20(7), 741–747. https://doi.org/10.1038/nm.3552

Bradley, M. O., Kraynak, A. R., Storer, R. D., & Gibbs, J. B. (1986). Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes. Proceedings of the National Academy of Sciences of the United States of America, 83(14), 5277–5281. https://doi.org/10.1073/pnas.83.14.5277

Cajero-Juárez, M., Avila, B., Ochoa, A., Garrido-Guerrero, E., Varela-Echavarría, A., Martínez de la Escalera, G., & Clapp, C. (2002). Immortalization of bovine umbilical vein endothelial cells: A model for the study of vascular endothelium. European Journal of Cell Biology, 81(1), 1–8. https://doi.org/10.1078/0171-9335-00213

Clapp, C., Thebault, S., Macotela, Y., Moreno-Carranza, B., Triebel, J., & Martínez de la Escalera, G. (2015). Regulation of blood vessels by prolactin and vasoinhibins. Advances in Experimental Medicine and Biology, 846, 83–95. https://doi.org/10.1007/978-3-319-12114-7_4

Clapp, C., & Weiner, R. I. (1992). A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology, 130(3), 1380–1386. https://doi.org/10.1210/endo.130.3.1311239

Comşa, Ş., Cîmpean, A. M., & Raica, M. (2015). The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Research, 35(6), 3147–3154.

Dakup, P. P., Porter, K. I., Little, A. A., Zhang, H., & Gaddameedhi, S. (2020). Sex differences in the association between tumor growth and T cell response in a melanoma mouse model. Cancer Immunology, Immunotherapy : CII, 69(10), 2157–2162. https://doi.org/10.1007/s00262-020-02643-3

García, C., Aranda, J., Arnold, E., Thébault, S., Macotela, Y., López-Casillas, F., Mendoza, V., Quiroz-Mercado, H., Hernández-Montiel, H. L., Lin, S.-H., Escalera, G. M. de la, & Clapp, C. (2008). Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A–dependent eNOS inactivation. The Journal of Clinical Investigation, 118(6), 2291–2300. https://doi.org/10.1172/JCI34508

Majewska, A., Wilkus, K., Brodaczewska, K., & Kieda, C. (2021). Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies. International Journal of Molecular Scienc

Attachment

Submitted filename: Response to Reviewers.docx

pone.0316983.s003.docx (66.8KB, docx)

Decision Letter 1

Mohamed Abdelkarim

8 Apr 2025

The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability

PONE-D-24-58885R1

Dear Dr. Clapp,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mohamed Abdelkarim

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Mohamed Abdelkarim

PONE-D-24-58885R1

PLOS ONE

Dear Dr. Clapp,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Mohamed Abdelkarim

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Plos one report.docx

    pone.0316983.s001.docx (15.6KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0316983.s003.docx (66.8KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files

    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES